Search

Filter Options

Active Development

Reset

Delivery Type

Reset

Duration Type

Reset

Developer

Reset

User

Reset

Hormonal

Reset

Development Stage

Reset

Potential MPT

Reset

API

Reset
View by user and type (hormonal or non-hormonal)
Displaying 41 - 50 of 243
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Chongqing Medical Equipment Factory Co., Ltd.
Development Stage: Marketed
Development Phase: Limited Market Availability
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Other
Development Stage: Lead Optimization
Development Phase: Discovery and Early Development
Alternative Name: Inhibition of Vas Propulsive Contractility
User: Male
Hormonal: No
Duration Type: Short-acting
Delivery Method: Oral
Developer: King's College, London
Development Stage: Lead Optimization
Development Phase: Discovery and Early Development
User: Female
Hormonal: Yes
Delivery Method: Transdermal
Developer: Viramal Limited
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal Gel, Vaginal, Other
Developer: Central Drug Research Institute, India, HLL Lifecare Limited
Development Stage: Regulatory
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: BioRings Intravaginal Ring
User: Female
Hormonal: No
Duration Type: Short-acting
Delivery Method: Vaginal Ring
Developer: BioRings, Weill Cornell Medical College, QPharma
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: Carboxy Terminus Peptide of β-human chorionic gonadotropin
User: Female
Hormonal: No
Developer: WHO, Talwar Research Foundation
Development Stage: Phase II
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: Nanocomposite Copper (Cu) IUD
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Tongji Medical College at Huazhong University of Science and Technology
Development Stage: Marketed
Development Phase: Limited Market Availability
Alternative Name: l'Amour®; Jeitosa®
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier
Developer: Cupid Ltd.
Development Stage: SRA/WHO PQ Approved
Development Phase: Limited Market Availability
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier
Developer: Cupid Ltd.
Development Phase: Limited Market Availability

Pages

Displaying 41 - 50 of 70
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Merck
Development Stage: Prototype Development
Alternative Name: Metalloprotease
Target
User: Female
Hormonal: No
Developer: Oregon Health & Science University
Development Stage: Target Validation
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Microchips Biotech, Inc.
Development Stage: Prototype Development
Target
User: Male
Hormonal: No
Developer: University of Kansas Medical Center, University of Minnesota
Development Stage: Target Validation
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal Gel
Developer: Washington University
Development Stage: Compound ID/Selection
Alternative Name: Lavax Vaginal Suppository
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal, Other
Developer: Lavax
Development Stage: Lead Optimization
User: Male
Hormonal: No
Delivery Method: Oral
Developer: North Shore University Hospital in New York
Development Stage: Lead Optimization
Alternative Name: Nomegestrol acetate (NOMAC) vaginal ring
User: Female
Hormonal: Yes
Delivery Method: Vaginal Ring
Developer: Merck
Development Stage: Prototype Development
User: Female, Male
Duration Type: Short-acting, Pericoital
Delivery Method: Injectable, Vaginal, Other, Other
Development Stage: Lead Optimization
User: Male
Hormonal: Yes
Developer: University of Kansas Medical Center, University of Minnesota
Development Stage: Lead Optimization

Pages

Displaying 91 - 100 of 121
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: HLL Lifecare Limited
Development Stage: Phase II
User: Female
Hormonal: No
Duration Type: Short-acting
Delivery Method: Vaginal, Other
Developer: Indian Council for Medical Research, Talwar Research Foundation
Development Stage: Phase II
Alternative Name: Mini-pill cream
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Transdermal
Developer: Viramal Limited
Development Stage: Pre-clinical
Alternative Name: Quinacrine Sterilization (QS)
User: Female
Hormonal: No
Duration Type: Permanent
Delivery Method: Intrauterine
Developer: ISAF
Development Stage: Phase III
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Subdermal
Developer: Tehran University
Development Stage: Pre-clinical
Alternative Name: Reversible inhibition of sperm under guidance (RISUG)
User: Male
Hormonal: No
Duration Type: Long-acting
Delivery Method: Vas Deferens
Developer: Indian Council for Medical Research, Indian Institute of Technology, Kharagpur
Development Stage: Phase III
ROC
Alternative Name: Ulipristal acetate (UPA) Oral
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Oral
Developer: HRA Pharma, NICHD
Development Stage: Phase II
Alternative Name: C31G Vaginal Gel
User: Female
Hormonal: No
Duration Type: Short-acting
Delivery Method: Vaginal Gel
Developer: Adamis Pharmaceuticals
Development Stage: Phase III
Alternative Name: SCHIELD Biodegradable MPT Implant
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: RTI International
Development Stage: Pre-clinical
Alternative Name: Shepard Medical Intra Vas Device (IVD)
User: Male
Hormonal: No
Duration Type: Long-acting
Delivery Method: Vas Deferens
Developer: Shepherd Medical Company
Development Stage: Phase I

Pages

Displaying 21 - 30 of 52
Alternative Name: GyneFix 330
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Contrel Research, Belgium
Development Stage: SRA/WHO PQ Approved
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Shenyang Liren Medical & Technological Co.
Development Stage: Marketed
Alternative Name: Copper IUD for Nulliparous Women, Smaller Copper IUD T380
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Implementos Plasticos, Ltd., Mexico City
Development Stage: SRA/WHO PQ Approved
Alternative Name: SCu300 Intrauterine Devices, empira™
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: OCON Medical Ltd.
Development Stage: SRA/WHO PQ Approved
Alternative Name: LNG Contraceptive IUS (LCS); LCS16
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Bayer HealthCare
Development Stage: SRA/WHO PQ Approved
Alternative Name: Zarin; Femplant; Trust; Sino-implant (II)
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: FHI 360, Shanghai Dahua Pharmaceuticals, Ltd.
Development Stage: Marketed
Alternative Name: Levosert (U.K.); Erlacela (Portugal); Donasert (Romania); Avibela
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Actavis, Medicines360
Development Stage: SRA/WHO PQ Approved
Alternative Name: FC-Patch Low; Gestodene (GES) + ethinyl estradiol (EE) Patch
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Transdermal
Developer: WHO HRP, Bayer HealthCare, Gedeon Richter Plc.
Development Stage: SRA/WHO PQ Approved
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: 7Med Industrie, France
Development Stage: Regulatory
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Mona Lisa N.V.
Development Stage: SRA/WHO PQ Approved

Pages

CSV